The Europe, U.S., China, and Japan Acute Respiratory Distress Syndrome (ARDS) Market is expected to grow with a CAGR of 9.9% in the forecast period of 2023 to 2030. The years considered for the study are as mentioned below.
Access full Report @ https://www.databridgemarketresearch.com/ko/reports/europe-us-china-and-japan-acute-respiratory-distress-syndrome-ards-market
The Europe, U.S., China, and Japan acute respiratory distress syndrome (ARDS) market is highly fragmented and has a number of key players. The market has witnessed increased strategic developments owing to a favourable market scenario.
The major players dealing in Europe, U.S., China, and Japan acute respiratory distress syndrome (ARDS) market are introducing a strong range of products launching new products, and adopting strategic initiatives such as acquisition, agreements, business expansion, awards and recognition in the market. This helped companies to maximize sales with an enhanced product portfolio.
Gilead Sciences, Inc., is the dominating player in the Europe, U.S., China, and Japan Acute Respiratory Distress Syndrome (ARDS) Market. The other key players existing in the market are Drägerwerk AG & Co. KGaA, Fisher & Paykel Healthcare Limited., LivaNova PLC, Fresenius SE & Co. KGaA, Besmed Health Business Corp., Armstrong Medical, Smiths Medical, ResMed, ALung Technologies, Inc., Medtronic, F. Hoffmann-La Roche Ltd, Hamilton Medical, nice Neotech Medical Systems Pvt. Ltd., Pfizer Inc., WEINMANN Emergency Medical Technology GmbH + Co. KG, NIPRO, Terumo Medical Corporation, Getinge AB., EUROSETS and among others.
Gilead Sciences, Inc.
Gilead Sciences, Inc., is headquartered in California, U.S. and was founded in 1987. The company focuses on discovering and developing therapeutics for people with life-threatening diseases. The various product categories of the company include HIV/AIDS, COVID-19, liver diseases, hematology/oncology, cardiovascular, and inflammation/respiratory, among which inflammation/respiratory are the market focused categories.
For Instance,
- In July 2020, Gilead Sciences Inc. initiated clinical testing of an Inhaled Solution of Remdesivir for Potential Outpatient Treatment of COVID-19. This testing helped the company enhance its antiviral product portfolio, thereby strengthening its footprint in the market
The company has a wide presence across North America, Europe, and Asia-Pacific. In addition, the company also generates its revenue from various subsidiaries, including Asegua Therapeutics LLC (U.S.), Forty Seven, Inc. (U.S.), Forty Seven Holdings, LLC. (U.S.), Gilead Alberta, LLC (U.S.), Gilead Apollo, LLC.(U.S.), Gilead Biopharmaceutics US LLC (U.S.) among others.
Terumo Medical Corporation
Terumo Medical Corporation is headquartered in Japan and was founded in 1921. The company focuses on giving a large portfolio of medical products for clinical practices. The company has the following business segments such as cardiac and vascular company, general hospital company and blood and cell technologies company, among which cardiac and vascular company is the focused business segment. The various product categories of the company include Terumo Interventional Systems, Neurovascular Division, Cardiovascular Division, and Vascular Graft Division, among which Cardiovascular Division is a market-focused category.
For Instance,
- In April 2020, Terumo Corporation doubled the extracorporeal membrane oxygenation ECMO Production and Supply. ECMO consists of an oxygenator and centrifugal pump, which is used for patients with severe respiratory failure. This will help the company to increase its market growth the market
The company has a presence across North America, Europe, Asia-Pacific, and South America. In addition, the company also generates its revenue from various subsidiaries, including Terumo BCT, Inc. (U.S.), MicroVention, Inc. (U.S.), Terumo Aortic Limited (U.K.), and Terumo (Thailand) Co., Ltd. (Thailand), Terumo Penpol (India) among others.
Getinge AB
Getinge AB is headquartered in Gothenburg, Sweden, and was founded in 1904. This company is focused on providing hospitals and life sciences institutions with various medical products and improving clinical results. The company has the following business segments such as acute care therapies, life sciences, surgical workflows, and group functions which acute care therapies businesses is the focused business segment. The various product categories of the company include Hospitals, Life Sciences, among which Extracorporeal Life Support is the market focused category.
For instance,
- In October 2020, Getinge added new features in mechanical ventilation called NAVA- Neurally Adjusted Ventilatory Assist. NAVA can help all types of patients breathe, from tiny premature babies weighing a few hundred grams to frail older patients. This has helped the company to increase its revenue in the market
The company has a presence across North America, Europe, Asia-Pacific, and South America. In addition, the company also generates its revenue from various subsidiaries, including Getinge Australia Pty Ltd. (Australia), Getinge Belgium NV. (Belgium), Getinge do Brasil (Brazil), Equipamentos Medicos Ltda Maquet Colombia S.A.S. (Colombia), Getinge France SAS (France) among others.
